Front. Immunol.Frontiers in ImmunologyFront. Immunol.1664-3224Frontiers Media S.A.10.3389/fimmu.2025.1659224ImmunologyCorrectionCorrection: RvE1 attenuates polymicrobial sepsis-induced cardiac dysfunction and enhances bacterial clearanceChenJianmin1*PurvisGareth S. D.2CollottaDebora3AI ZoubiSura14SugimotoMichelle A.1CacaceAntonino15MartinLukas16ColasRoman A.1CollinoMassimo3DalliJesmond1ThiemermannChristoph1*1Barts and the London School of Medicine and Dentistry, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom2Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom3Department of Drug Science and Technology, University of Turin, Turin, Italy4Department of Basic Medical Sciences, School of Medicine, Al-Balqa Applied University, As-Salt, Jordan5Diabetes Complication Research Centre, School of Medicine, UCD Conway Institute, University College Dublin, Dublin, Ireland6Department of Intensive Care and Intermediate Care, RWTH University Hospital Aachen, Aachen, Germany
Edited and Reviewed by: Niccolo Terrando, Duke University, United States
*Correspondence: Jianmin Chen, jianmin.chen@qmul.ac.uk; Christoph Thiemermann, c.thiemermann@qmul.ac.uk
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
A Correction on RvE1 attenuates polymicrobial sepsis-induced cardiac dysfunction and enhances bacterial clearance By Chen J, Purvis GSD, Collotta D, Al Zoubi S, Sugimoto MA, Cacace A, Martin L, Colas RA, Collino M, Dalli J and Thiemermann C (2020). Front. Immunol. 11:2080. doi: 10.3389/fimmu.2020.02080polymicrobial sepsisresolvin E1bacterial clearanceimmune responsecardiomyopathysection-in-acceptanceInflammation
There was a mistake in Figure 3A as published. The previous image of Figure 3A (MHCII vs. SSC-A scatter plot) was selected from a mouse in the 24-hour post-CLP group that had received RvE1 treatment, as we initially understood that RvE1-treated mice were also subjected to 24-hour CLP. However, to avoid any further confusion, we have now replaced this scatter plot with an image from a mouse subjected to CLP without RvE1 treatment. This change more accurately reflects the legend of Figure 3A: “(A) Flow cytometry gating strategy of mouse peritoneal immune cells 24 h post-CLP”. The corrected Figure 3 and its caption appear below.
RvE1 treatment enhances MHC II- macrophage recruitment in peritoneal cavity. Mice underwent CLP surgery. One hour after CLP, mice were treated with either RvE1 (1 μg/mouse i.v.) or vehicle (100 μl PBS, 0.1% Ethanol). (A) Flow cytometry gating strategy of mouse peritoneal immune cells 24 h post-CLP. (B) Scattergrams illustrating monocyte/macrophage (identified as Ly6G-CD64+) and neutrophil (identified as Ly6G+CD64-) positive events in peritoneal lavages from CLP mice with vehicle or RvE1 treatment. (C, D) Cumulative data for peritoneal CD64+ monocytes/macrophages and Ly6G+ neutrophils. (E) Scattergrams illustrating macrophage (identified as CD64highLy6Clow) and monocyte (identified as CD64lowLy6Chigh) positive events in peritoneal lavages from CLP mice with vehicle or RvE1 treatment. (F, G) Cumulative data for peritoneal CD64highLy6Clow macrophages and CD64lowLy6Chigh monocytes. (H) Scattergrams illustrating MHC II- macrophage and MHC II+ macrophage positive events in peritoneal lavages from CLP mice with vehicle or RvE1 treatment. (I, J) Cumulative data for peritoneal MHC II- macrophages and MHC II+ macrophages. Data are expressed as mean ± SEM of four mice for vehicle group and five mice for RvE1 treatment group. Data were analyzed by unpaired Student’s t-test. *P< 0.05 versus CLP + Vehicle group.
Flow cytometry analysis compares immune cell populations under CLP with or without RvE1 treatment. Panels A and B show gating strategies for identifying live myeloid cells, monocytes/macrophages, neutrophils, and subpopulations based on CD64, Ly6G, and MHCII expression. Panels C to J present statistical graphs indicating the total number of specific cell types, revealing significant differences between treatments. RvE1 impacts monocyte and macrophage populations, as shown by flow data and bar charts.Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.